The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial.
To determine whether the functional mu-opioid receptor (OPRM1) Asn40Asp variant predicts the comparative efficacy of different forms of NRT, we conducted a clinical trial of transdermal nicotine (TN) vs nicotine nasal spray (NS) in 320 smokers of European ancestry. Smokers carrying the OPRM1 Asp40 variant (n=82) were significantly more likely than those homozygous for the Asn40 variant (n=238) to be abstinent at the end of treatment, and reported less mood disturbance and weight gain. The genotype effect on treatment outcome was most pronounced among smokers receiving TN, particularly during the 21 mg dose phase. Smokers who carry the OPRM1 Asp40 variant are likely to have a favorable response to TN and may benefit from extended therapy with the 21 mg dose.
Department of Psychiatry, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA. clerman@mail.med.upenn.edu
C
C
Lerman
E P
EP
Wileyto
F
F
Patterson
M
M
Rukstalis
J
J
Audrain-McGovern
S
S
Restine
P G
PG
Shields
V
V
Kaufmann
D
D
Redden
N
N
Benowitz
W H
WH
Berrettini
D000279:Administration, Cutaneous; D000281:Administration, Intranasal; D000328:Adult; D001216:Asparagine / Q000235:genetics; D001224:Aspartic Acid / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D014644:Genetic Variation / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D017450:Receptors, Opioid, mu / Q000235:genetics*; D012907:Smoking / Q000188:drug therapy* / Q000235:genetics*; D013997:Time Factors
C485764:OPRM1 protein, human; D017450:Receptors, Opioid, mu; D001224:Aspartic Acid; D009538:Nicotine; D001216:Asparagine